Completed PHASE1 INTERVENTIONAL 1-arm NCT05193851

Evaluate the Safety and Pharmacokinetics of Ricolinostat

A Phase I Clinical Study Evaluating the Safety and Pharmacokinetics of Ricolinostat in Chinese Subjects

Sponsor: Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

Conditions Peripheral Nervous System Diseases

Updated 6 times since 2022 Last updated: Mar 30, 2023 Started: Jan 12, 2022 Primary completion: Jan 30, 2022 Completion: Jan 6, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05193851, this PHASE1 trial focuses on Peripheral Nervous System Diseases and remains completed. Sponsored by Beijing 3E-Regenacy Pharmaceuticals Co., Ltd., it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2023 — Jul 2024 [monthly]

Completed PHASE1
Apr 2023 — May 2023 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Apr 2022 — Apr 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2022 — Apr 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

Data source: Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changchun, China